Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks

CVS Health (CVS) Stock Forecast & Price Target

CVS Health logo
$72.13 +0.20 (+0.28%)
Closing price 03:59 PM Eastern
Extended Trading
$72.06 -0.07 (-0.10%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare

CVS Health - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Buy
Based on 22 Analyst Ratings
Sell
0
Hold
1
Buy
21

Based on 22 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Buy." Out of the 22 analysts, 1 has given a hold rating, 19 have given a buy rating, and 2 have given a strong buy rating for CVS.

Consensus Price Target

$77.56
7.52% Upside
According to the 22 analysts' twelve-month price targets for CVS Health, the average price target is $77.56. The highest price target for CVS is $84.00, while the lowest price target for CVS is $65.00. The average price target represents a forecasted upside of 7.52% from the current price of $72.13.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVS Analyst Ratings Over Time

TypeCurrent Forecast
8/28/24 to 8/28/25		1 Month Ago
7/29/24 to 7/29/25		3 Months Ago
5/30/24 to 5/30/25		1 Year Ago
8/29/23 to 8/28/24
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
19 Buy rating(s)
17 Buy rating(s)
16 Buy rating(s)
12 Buy rating(s)
Hold
1 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
10 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$77.56$74.94$75.27$73.24
Forecasted Upside7.52% Upside24.90% Upside17.62% Upside27.95% Upside
Consensus Rating
Buy
Moderate Buy
Moderate Buy
Moderate Buy

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

CVS Health Stock vs. The Competition

TypeCVS HealthMedical CompaniesS&P 500
Consensus Rating Score
3.05
2.78
2.53
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside7.81% Upside14,596.16% Upside9.99% Upside
News Sentiment Rating
Positive News

See Recent CVS News
Positive News
Positive News
Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/26/2025Cantor Fitzgerald
4 of 5 stars		Sarah James
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight ➝ Overweight$78.00+9.52%
8/18/2025UBS Group
3 of 5 stars		Kevin Caliendo
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeNeutral ➝ Buy$67.00 ➝ $79.00+15.23%
8/14/2025Baird R W
2 of 5 stars		 UpgradeHold ➝ Strong-Buy
8/14/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Michael Ha
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeNeutral ➝ Outperform$71.00 ➝ $82.00+24.41%
8/4/2025Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy
8/1/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Erin Wright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOverweight ➝ Overweight$80.00 ➝ $82.00+31.12%
8/1/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Andrew Mok
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOverweight ➝ Overweight$79.00 ➝ $80.00+28.80%
7/16/2025Bernstein Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetMarket Perform$78.00 ➝ $72.00+12.86%
6/30/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Brian Tanquilut
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$74.00 ➝ $80.00+16.43%
5/12/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating		David Macdonald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$82.00 ➝ $84.00+32.07%
5/6/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating		S. Baxter
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight ➝ Overweight$76.00 ➝ $84.00+25.20%
5/5/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Ben Hendrix
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOutperform ➝ Outperform$74.00 ➝ $81.00+19.23%
4/9/2025Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Ann Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOutperform ➝ Outperform$70.00 ➝ $76.00+12.36%
3/21/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Jessica Tassan
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOverweight ➝ Overweight$72.00 ➝ $74.00+7.70%
2/18/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Set Target$77.00+16.93%
2/18/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lisa Gill
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOverweight ➝ Overweight$80.00 ➝ $81.00+23.71%
2/13/2025Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Michael Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeMarket Perform ➝ Outperform$55.00 ➝ $75.00+18.61%
2/12/2025Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating		M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating		UpgradeHold ➝ Strong-Buy
2/11/2025Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight67.00 ➝ 70.00
1/30/2025Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy
1/27/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Elizabeth Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetOutperform ➝ Outperform$60.00 ➝ $65.00+15.59%
12/3/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$66.00 ➝ $66.00+11.73%
11/25/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating		C. Rhyee
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost TargetBuy ➝ Buy$73.00 ➝ $80.00+33.11%
5/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$95.00 ➝ $77.00+41.73%
5/2/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$85.00 ➝ $74.00+36.08%
12/22/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$94.00+19.56%
10/10/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower Target$93.00 ➝ $80.00+11.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 05:35 PM ET.


Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, August 26, 2025. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in CVS Health Co.:

  • CVS Health Co. recently reported strong quarterly earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial performance.
  • The company has shown a year-over-year revenue increase of over 8%, suggesting growth and resilience in its business model.
  • CVS Health Co. has a solid dividend yield of approximately 3.7%, providing investors with a reliable income stream through dividends.
  • Analysts have a generally positive outlook on the stock, with many rating it as a "buy" and setting price targets that reflect potential upside.
  • The current stock price is around $80, which is considered attractive given the company's strong fundamentals and growth prospects.

CVS Health
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in CVS Health Co. for these reasons:

  • The company's net margin is relatively low at 1.17%, which may indicate challenges in profitability compared to competitors.
  • CVS Health Co. has set its earnings guidance for FY 2025 lower than the previous year's EPS, which could signal potential headwinds in growth.
  • There is a high dividend payout ratio of 74.30%, which may raise concerns about the sustainability of dividend payments in the long term.
  • Recent insider trading activity, while not necessarily negative, could raise questions about the confidence of management in the company's future performance.
  • Market volatility and economic uncertainties could impact the stock's performance, making it a riskier investment in the current climate.

CVS Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $77.56, with a high forecast of $84.00 and a low forecast of $65.00.

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last year. There is currently 1 hold rating, 19 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CVS shares.

According to analysts, CVS Health's stock has a predicted upside of 7.52% based on their 12-month stock forecasts.

Over the previous 90 days, CVS Health's stock had 3 upgrades by analysts.

CVS Health has been rated by research analysts at Baird R W, Barclays, Bernstein Bank, Cantor Fitzgerald, Cowen, Jefferies Financial Group, Morgan Stanley, Robert W. Baird, and UBS Group in the past 90 days.

Analysts like CVS Health more than other "medical" companies. The consensus rating for CVS Health is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CVS compares to other companies.

Related Companies
Today's Ratings
Top-Rated Stocks
More Ratings Tools

This page (NYSE:CVS) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsoredtc pixel
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here.
Crypto 101 Media | Sponsoredtc pixel
INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off
Right now, we’re witnessing a monumental shift in the world.
Traders Agency | Sponsoredtc pixel
Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...
Brownstone Research | Sponsoredtc pixel
Small Washington, DC Group Could Crash US Stocks
New Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...
Altimetry | Sponsoredtc pixel
Think you missed gold’s boom? Think again
If you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...
Investors Alley | Sponsoredtc pixel
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...
Timothy Sykes | Sponsoredtc pixel
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...
Paradigm Press | Sponsoredtc pixel